Abstract
Background
Since the Randomized Aldactone Evaluation Study (RALES), the use of spironolactone is recommended in systolic heart failure (HF) patients that have been in New York Heart Association (NYHA) class III or IV. There is limited information on the use, side effects, and withdrawal rate of spironolactone in routine clinical practice.
Hypothesis
Side effects related to spironolactone use are more common than reported in clinical trials.
Methods
Patients who had moderate to severe left ventricular systolic dysfunction (LVSD) under optimized medical therapy were included. We introduced spironolactone in those with serum potassium (K+) ≤ 5 meq/L, and serum creatinine (Cr) ≤ 2.5 mg/dL. Spironolactone was withdrawn if serum K + ≥ 5.5 meq/L, serum Cr increased more than 30%− 50% of the baseline value, and/or if the patient had gynecomastia.
Results
We selected 134 patients followed in an HF clinic. In our sample, 56.7% of the patients (76 out of 134) were currently or had formerly been on spironolactone therapy. The rate of spironolactone withdrawal was 25% (19 out of 76). Reasons for suspension were hyperkalemia (17.1%), renal function deterioration (14.5%), gynecomastia (5.3% of males), and other reasons (1.3%).
Conclusion
Spironolactone side effects are common and are mostly related to effects on the angiotensin‐aldosterone axis. Our results reinforce the need to closely monitor serum K+ and Cr levels in patients treated with spironolactone, as its side effects are more common than reported in clinical trials. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: spironolactone; heart failure; hyperkalemia, renal function deterioration
Full Text
The Full Text of this article is available as a PDF (98.6 KB).
References
- 1. Pitt B MD, Zannad F MD, Remme WJ MD, Cody R MD, Castaigne A MD, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709–717. [DOI] [PubMed] [Google Scholar]
- 2. Pitt B MD, Zannad F MD, Remme WJ MD, Neaton J PhD, Martinez F MD, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348(14): 1309–1321. [DOI] [PubMed] [Google Scholar]
- 3. Tamirisa KP MD, Aaronson KD MD, MS, Koelling TM MD. Spironolactone‐induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J 2004; 148(6): 971–978. [DOI] [PubMed] [Google Scholar]
- 4. Juurlink DN MD, PhD, Mamdani MM Pharm. D, MPH, Lee DS MD, Kopp A BA, Austin PC PhD, et al.: Rates of Hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med 2004; 351(6): 543–551. [DOI] [PubMed] [Google Scholar]
- 5. Schepkens H MD, Vanholder R MD, PhD, Billiouw JM MD, Lameire N MD, PhD: Life‐threatening hyperkalemia during combined therapy with angiotensin converting enzyme inhibitors and spironolactone: An analysis of 25 cases. Am J Med 2001; 110: 438–441. [DOI] [PubMed] [Google Scholar]
- 6. Berry C MD, McMurray JJ MD. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: E8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Hauben M MD, MPH, Reich L MD, Gerrits CM Pharm.D, PhD. Reports of hyperkalemia after publication of RALES–a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006; 15(11): 775–783. [DOI] [PubMed] [Google Scholar]
- 8. Svensson M MD, Gustafsson F MD, Galatius S MD, Hildebrandt PR, MD, Atar D MD. Hyperkalemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ 2003; 327: 1141–1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ko DT MD, Juurlink DN MD, PhD, Mamdani MM Pharm.D, MPH, You JJ MD, Wang JT MSc, et al.: Appropriateness of spironolactone prescribing in heart failure patients: A population‐ based study. J Card Fail 2006; 12(3): 205–210. [DOI] [PubMed] [Google Scholar]
- 10. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416. [DOI] [PubMed] [Google Scholar]
- 11. Pitt B MD: Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 2003; 108: 1790–1794. [DOI] [PubMed] [Google Scholar]
- 12. Farquharson CA MBChB, MRCP, Struthers AD MD, FRCP: Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 1722–1728. [DOI] [PubMed] [Google Scholar]
- 13. Yee KM MRCP, Pringle SD MD, FRCP, Struthers AD MD, FRCP, FESC: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2002; 37(7): 1800–1807. [DOI] [PubMed] [Google Scholar]
- 14. Modena MG MD, FACC, FESC, Aveta P MD, Menozzi A MD, Rossi R MD: Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001; 141(1): 41–46. [DOI] [PubMed] [Google Scholar]